Folgen
Peter B. Gilbert
Peter B. Gilbert
Member, Fred Hutchinson Cancer Research Center, and Research Professor, Department of Biostatistics, University of Washington
Bestätigte E-Mail-Adresse bei scharp.org - Startseite
Titel
Zitiert von
Zitiert von
Jahr
Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine
LR Baden, HM El Sahly, B Essink, K Kotloff, S Frey, R Novak, D Diemert, ...
New England journal of medicine 384 (5), 403-416, 2021
98022021
Immune-correlates analysis of an HIV-1 vaccine efficacy trial
BF Haynes, PB Gilbert, MJ McElrath, S Zolla-Pazner, GD Tomaras, ...
New England Journal of Medicine 366 (14), 1275-1286, 2012
20732012
Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial
SP Buchbinder, DV Mehrotra, A Duerr, DW Fitzgerald, R Mogg, D Li, ...
The Lancet 372 (9653), 1881-1893, 2008
19792008
Human Immunodeficiency Virus Type 1 env Clones from Acute and Early Subtype B Infections for Standardized Assessments of Vaccine-Elicited Neutralizing …
M Li, F Gao, JR Mascola, L Stamatatos, VR Polonis, M Koutsoukos, ...
Journal of virology 79 (16), 10108-10125, 2005
12632005
Randomized, double‐blind, placebo‐controlled efficacy trial of a bivalent recombinant glycoprotein 120 HIV‐1 vaccine among injection drug users in Bangkok, Thailand
P Pitisuttithum, P Gilbert, M Gurwith, W Heyward, M Martin, ...
The Journal of infectious diseases 194 (12), 1661-1671, 2006
10302006
Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial
PB Gilbert, DC Montefiori, AB McDermott, Y Fong, D Benkeser, W Deng, ...
Science 375 (6576), 43-50, 2022
8912022
Evidence for antibody as a protective correlate for COVID-19 vaccines
KA Earle, DM Ambrosino, A Fiore-Gartland, D Goldblatt, PB Gilbert, ...
Vaccine 39 (32), 4423-4428, 2021
8182021
Tiered categorization of a diverse panel of HIV-1 Env pseudoviruses for assessment of neutralizing antibodies
MS Seaman, H Janes, N Hawkins, LE Grandpre, C Devoy, A Giri, ...
Journal of virology 84 (3), 1439-1452, 2010
7182010
Efficacy trial of a DNA/rAd5 HIV-1 preventive vaccine
SM Hammer, ME Sobieszczyk, H Janes, ST Karuna, MJ Mulligan, ...
New England Journal of Medicine 369 (22), 2083-2092, 2013
7052013
Effect of dengue serostatus on dengue vaccine safety and efficacy
S Sridhar, A Luedtke, E Langevin, M Zhu, M Bonaparte, T Machabert, ...
New England Journal of Medicine 379 (4), 327-340, 2018
6632018
Barriers to antiretroviral adherence for patients living with HIV infection and AIDS in Botswana
S Weiser, W Wolfe, D Bangsberg, I Thior, P Gilbert, J Makhema, ...
JAIDS Journal of Acquired Immune Deficiency Syndromes 34 (3), 281-288, 2003
6332003
Breastfeeding plus infant zidovudine prophylaxis for 6 months vs formula feeding plus infant zidovudine for 1 month to reduce mother-to-child HIV transmission in Botswana: a …
I Thior, S Lockman, LM Smeaton, RL Shapiro, C Wester, SJ Heymann, ...
Jama 296 (7), 794-805, 2006
5302006
Efficacy of the mRNA-1273 SARS-CoV-2 vaccine at completion of blinded phase
HM El Sahly, LR Baden, B Essink, S Doblecki-Lewis, JM Martin, ...
New England Journal of Medicine 385 (19), 1774-1785, 2021
5052021
Increased HIV-1 vaccine efficacy against viruses with genetic signatures in Env V2
M Rolland, PT Edlefsen, BB Larsen, S Tovanabutra, E Sanders-Buell, ...
Nature 490 (7420), 417-420, 2012
4872012
Prevalence and predictive value of intermittent viremia with combination HIV therapy
DV Havlir, R Bassett, D Levitan, P Gilbert, P Tebas, AC Collier, MS Hirsch, ...
Jama 286 (2), 171-179, 2001
4752001
Correlation between immunologic responses to a recombinant glycoprotein 120 vaccine and incidence of HIV-1 infection in a phase 3 HIV-1 preventive vaccine trial
PB Gilbert, ML Peterson, D Follmann, MG Hudgens, DP Francis, ...
The Journal of infectious diseases 191 (5), 666-677, 2005
4682005
Vaccine-induced Env V1-V2 IgG3 correlates with lower HIV-1 infection risk and declines soon after vaccination
NL Yates, HX Liao, Y Fong, A DeCamp, NA Vandergrift, WT Williams, ...
Science translational medicine 6 (228), 228ra39-228ra39, 2014
4662014
Vaccine-induced plasma IgA specific for the C1 region of the HIV-1 envelope blocks binding and effector function of IgG
GD Tomaras, G Ferrari, X Shen, SM Alam, HX Liao, J Pollara, ...
Proceedings of the National Academy of Sciences 110 (22), 9019-9024, 2013
4452013
Antibody-dependent cellular cytotoxicity-mediating antibodies from an HIV-1 vaccine efficacy trial target multiple epitopes and preferentially use the VH1 gene family
M Bonsignori, J Pollara, MA Moody, MD Alpert, X Chen, KK Hwang, ...
Journal of virology 86 (21), 11521-11532, 2012
4392012
Genetic diversity and protective efficacy of the RTS, S/AS01 malaria vaccine
DE Neafsey, M Juraska, T Bedford, D Benkeser, C Valim, A Griggs, ...
New England Journal of Medicine 373 (21), 2025-2037, 2015
4102015
Das System kann den Vorgang jetzt nicht ausführen. Versuchen Sie es später erneut.
Artikel 1–20